KRAS degradation averts PDAC chemoresistance

被引：0
|
作者：
Leonhardt, Laura [1 ,2 ,3 ]
Hebrok, Matthias [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Tech Univ Munich, TUM Sch Med & Hlth, Munich, Germany
[2] Tech Univ Munich, Ctr Organoid Syst, Garching, Germany
[3] Inst Diabet & Organoid Technol, Helmholtz Diabet Ctr, Helmholtz Zentrum Munchen, Neuherberg, Germany
[4] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Munich, Germany
[5] German Ctr Diabet Res DZD, Neuherberg, Germany
[6] Univ Calif San Francisco, Diabet Ctr, Dept Med, San Francisco, CA 94143 USA
来源：
NATURE CANCER | 2024年 / 5卷 / 03期
关键词：
D O I：
10.1038/s43018-023-00708-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
引用
收藏
页码：375 / 377
页数：3
相关论文
共 50 条
  • [41] Par-4 activation restrains EMT-induced chemoresistance in PDAC by attenuating MDM-2
    Ahmad, Syed Mudabir
    Nayak, Debasis
    Mir, Khalid Bashir
    Faheem, Mir Mohd
    Nawaz, Shah
    Yadav, Govind
    Goswami, Anindya
    PANCREATOLOGY, 2020, 20 (08) : 1698 - 1710
  • [42] Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response
    Mehdi, Maahum
    Annunzio, Kaitlin
    Taylor, Bradley W.
    Szabo, Aniko
    Shreenivas, Aditya V.
    Chakrabarti, Sakti
    Thomas, James P.
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Clarke, Callisia
    Hall, William A.
    Erickson, Beth
    Thapa, Bicky
    Ahmed, Gulrayz
    George, Ben
    Kamgar, Mandana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [43] MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC).
    Mehdi, Maahum
    Thalji, Samih Z.
    Shreenivas, Aditya V.
    Chakrabarti, Sakti
    Thomas, James P.
    Christians, Kathleen K.
    Evans, Douglas B.
    Hall, William A.
    Erickson, Beth
    Thapa, Bicky
    Ahmed, Gulrayz
    Yazdanpanah, Omid
    Kurzrock, Razelle
    Aldakkak, Mohammed
    Holden, Mary Beth
    Ben George
    Tsai, Susan
    Oxencis, Carolyn
    McFall, Thomas
    Kamgar, Mandana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16260 - E16260
  • [44] Mutant KRAS/BRAF Reprograms the Enhancer Landscape via GATA1 to Drive Chemoresistance
    Wu, Rentian
    Nie, Qian
    Wang, Zhiquan
    Kubica, Philp
    Bouchonville, Kelly J.
    Jerde, Calvin R.
    Shrestha, Shikshya
    Offer, Steven M.
    Diasio, Robert B.
    MOLECULAR BIOLOGY OF THE CELL, 2018, 29 (26)
  • [45] Wild-type RAS/MAPK signaling complexes mediate adaptive resistance to KRAS inhibition in PDAC.
    Ge, Xiangyu
    Ruiz, Christian F.
    Li, Wenxue
    Quinones-Aviles, Yanixa
    Muzumdar, Mandar Deepak
    CANCER RESEARCH, 2022, 82 (22) : 95 - 96
  • [46] Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation
    Zhang, Junlei
    Song, Jinyuan
    Tang, Shima
    Zhao, Yaxing
    Wang, Lin
    Luo, Yandong
    Tang, Jianghui
    Ji, Yongtao
    Wang, Xun
    Li, Taohong
    Zhang, Hui
    Shao, Wei
    Sheng, Jianpeng
    Liang, Tingbo
    Bai, Xueli
    CELL REPORTS, 2023, 42 (06):
  • [47] Tumor-derived interleukin 35 facilitates the gemcitabine resistance in pancreatic adenocarcinoma by mediating the dissemination of chemoresistance among PDAC cells
    Huang, Chongbiao
    Sun, Huizhi
    Chang, Antao
    Hao, Jihui
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Combined inhibition of the MAPK and Hippo pathways drives efficacious tumor suppression in a faithful model of mutant Kras (KPC) PDAC
    Chakravarti, Deepavali
    Muller, Florian
    Gyuris, Jeno
    Baloglu, Erkun
    Kunnimalayiaan, Selvi
    Olson, Jill
    Shacham, Sharon
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [49] Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2 (vol 74, pg 7430, 2014)
    Tao, Shasha
    Wang, Shue
    Moghaddam, Seyed Javad
    Ooi, Aikseng
    Chapman, Eli
    Wong, Pak K.
    Zhang, Donna D.
    CANCER RESEARCH, 2019, 79 (05) : 1015 - 1015
  • [50] The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).
    Lou, Emil
    Xiu, Joanne
    Baca, Yasmine
    Walker, Phillip
    Manji, Gulam Abbas
    Gholami, Sepideh
    Saeed, Anwaar
    Philip, Philip Agop
    Prakash, Ajay
    Astsaturov, Igor A.
    Botta, Greg
    Abushahin, Laith I.
    Sohal, Davendra
    Lenz, Heinz Josef
    Shields, Anthony Frank
    Nabhan, Chadi
    El Deiry, Wafik S.
    Seeber, Andreas
    Korn, Wolfgang Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345